MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale

LYON, France--(BUSINESS WIRE)---- $MAAT--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont. With a research report named “Echec et MaaT”, Gilbert Dupont / Groupe Société Générale initiated coverage of MaaT Pharma on April 4th, 2024 with a Buy recommendation